Skip to main content
Equibles

BLRX · BioLineRx Ltd.

Track BLRX — free

Use BLRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BLRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.11 -0.10 (-4.72%)
Rebalance outlook locked
Market Cap
$11.02M
Shares
4.98M
Volume · Oct 21 1812 Avg daily vol (3M) 17.32K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.21 Open$2.07 Day$2.07–2.21 52W close$1.98–3.78 Avg vol 30d16K Short int146K · 2.9% float · 11.1d Short vol46% Last earningsAug 31, 2026 DataJan 2020–Oct 2026

Up next

Next earnings call
Dec 3, 2026 Est · unconfirmed · in 6 wks
Q3 2025 earnings call transcript
Date not confirmed

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.39M
Trailing 12 months
Net income (TTM)
−$10.14M
Trailing 12 months
Revenue growth YoY
-3.3%
Year over year
Operating margin
-874.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+16.9%
Year over year · more shares
Price change (1Y)
-40.8%
Trailing year
Short interest
2.9%
Latest settlement · 11.1 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
· $0 −$18.55M '23 Q2 · $5.39M $484,000 '24 Q2 ▼94.4% $304,000 −$3.94M '25 Q2 LATEST ▼3.3% $294,000 −$4.34M '26 Q2

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −20%
below
Price vs 50-day avg −12%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 13%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −9%
trailing
6-month return −28%
trailing
YTD return −20%
this year
Relative strength −36%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.92% of float · ▼ -0.2% MoM · 11.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
14 holders — mid 3-yr range
Squeeze score 53
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 60%
annualized · 1-yr
Max drawdown −48%
past year
ATR 7.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−20% Bearish
Price vs 50-day avg
−12% Bearish
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
13% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.92% of float · ▼ -0.2% MoM · 11.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
14 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 13% Range high $4
vs 200-day avg -20% vs 50-day avg -12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BLRX
BioLineRx Ltd.
this stock
$11.02M -20.1% — — 2.9%
VRTX
Vertex Pharmaceuticals Inc
 $131.39B +13.5% +46.2% 30.2 1.8%
MRNA
Moderna, Inc.
 $96.65B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.13B +4.6% +20.8% 20.0 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
14
% held
2.1%
Net QoQ
+75.8K sh
Top holder
SUSQUEHANNA INTERNATIONAL…
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
145.6K
Days to cover
11.1d
Change
-233 sh
View
Short Volume
Short vol %
46%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
1.0K
Value
$2.5K
As of
Sep 22, 2026
View
Off-Exchange
Off-exchange %
20.2%
Week of
Sep 14, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
F-1
Filed
Sep 25, 2026
This year
17
View
Exempt Offerings
Offering
$3.8M
Filed
Sep 9, 2026
View
Earnings & Events
Webcasts
Last webcast
Aug 31, 2026
View

Performance

5D 20D 120D MTD YTD
BLRX +2.1% -8.9% -27.9% -5.8% -20.1%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY +3.2% -8.3% -36.0% -6.6% -32.8%
Key facts CIK 1498403 CUSIP 09071M304 Visit website Investor relations